Adults with type 2 diabetes and chronic kidney disease using the nonsteroidal mineralocorticoid receptor antagonist finerenone have lower risks for pneumonia and COVID-19, according to findings published in JAMA Network Open. Read more in Healio.
Finerenone may lower risks for pneumonia, COVID-19 in adults with type 2 diabetes and CKD
